Sangamo Looks Forward After Shire Returns Hemophilia Rights

Sangamo Biosciences touted the progress of its in vivo protein replacement platform (IVPRP) as it reported that Shire relinquished its rights to hemophilia programs under the companies' three-year-old collaboration, but investors were wary about the loss of an important alliance for two out or four partnered programs as well as the exchange of milestone fees for total control of preclinical assets.